Renal denervation in patients with Stage 3 or 4 CKD and resistant hypertension did not significantly reduce median central blood pressure at 6 months (127/75 to 118/70 mm Hg; P=0.13).
Does renal denervation improve central blood pressures and arterial stiffness in patients with Stage 3 or Stage 4 CKD and resistant hypertension?
In patients with Stage 3-4 CKD and resistant hypertension, renal denervation significantly improved office blood pressures up to 24 months, but did not significantly change central blood pressures, 24-hour ambulatory pressures, or pulse wave velocity.
p-value: p=.13
Background: Central aortic blood pressures and arterial stiffness are better indicators of cardiovascular outcomes than brachial blood pressures. However, their response to renal denervation (RDN) in patients with Stage 3 and Stage 4 chronic kidney disease (CKD) has not yet been examined. Objective: To evaluate the impact of RDN on central blood pressures (CBP), brachial (office and ambulatory) blood pressures, arterial stiffness, glomerular filtration rate (GFR), 24-hour urine protein, and selective cardiac parameters observed on echocardiograms. Design: Single-center, single-arm with pre-/post-RDN follow-up. Setting: Patients were recruited from the multidisciplinary CKD clinic, Regina General Hospital, Canada. Patients: About 25 consecutive patients with Stage 3 or Stage 4 CKD and resistant hypertension, with no radiological or laboratory evidence of secondary causes of hypertension. Measurements: The key measurements were CBP, pulse wave velocity, ambulatory 24-hour blood pressure, office blood pressures on BP Tru, GFR, 24-hour urine protein and sodium, dose and number of blood pressure medication and doses. Methods: The primary outcome measure was the change in CBP from baseline to 6 months post-RDN. Secondary outcome measures included changes in CBP, office blood pressure, 24-hour ambulatory pressures, pulse wave velocity, kidney function (eGFR and 24-hour protein excretion), and the change in the number and dose of medications during the 2-year follow-up period. The primary outcome and the secondary outcomes were evaluated using a Friedman’s analysis of variance (ANOVA) and Wilcoxon signed-rank test for changes from post RDN procedure. Bonferroni correction was used to adjust P values for multiple testing. A two-sided alpha of .05 was used. Results: Median central blood pressures (mm Hg) were 127/75 at baseline versus 118/70 at 6 months and 118/67 at 24 months ( P = .13). Median office blood pressures (mm Hg) were 148/76 at baseline versus 135/75 at 6 months and 133/75 at 24 months ( P ≤ .001). Median ambulatory 24-hour day (mm Hg) was 148/64 at baseline and 146/68 at 6 months and 152/67 at 24 months ( P = .60). Median pulse wave velocity (m/s) at baseline was 13.8 at baseline versus 13.3 m/s at 6 months and 12.3 at 12 months’ time ( P = .62). Estimated glomerular filtration rate (mL/min/1.73m 2 ) at baseline was 37, at 6 months was 36 and 34 at 24 months ( P = .33). Limitations: Single-center study, with no sham arm. Conclusions: Our study demonstrates that there was a significant improvement in office blood pressures from baseline to 6 months, maintained to 24 months. There was a numerical improvement in central pressures, and pulse wave velocity at 6 and 24 months, with no sustained changes noted in 24-hour blood pressure. Kidney function remained at or near baseline throughout the 24 months of observation. Trial registration: ClinicalTrials.gov (NCT01832233).
Prasad et al. (Tue,) conducted a other in Stage 3 and Stage 4 chronic kidney disease (CKD) and resistant hypertension (n=25). Renal denervation (RDN) vs. Baseline was evaluated on Change in central blood pressures (CBP) from baseline to 6 months post-RDN (p=.13). Renal denervation in patients with Stage 3 or 4 CKD and resistant hypertension did not significantly reduce median central blood pressure at 6 months (127/75 to 118/70 mm Hg; P=0.13).